Apogenix inks cancer drug development deal for China

John Carroll

Germany's , which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize its lead immuno-oncology candidate APG101 in Macao, and Hong Kong.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS